Dianthus Therapeutics DNTH Cash Flow Statement
| TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | TTM Q4 '24 | TTM Q3 '24 | ||
|---|---|---|---|---|---|---|
| -$126.35M-88.3% | -$114.75M-102% | -$100.73M-101% | -$84.97M-95.1% | -$67.09M-55.6% | ||
| $110K+22.2% | $108K+28.6% | $101K+32.9% | $96K-79.8% | $90K-90.2% | ||
| $20.73M+114% | $18.78M+167% | $16.17M+267% | $12.89M+345% | $9.7M+261% | ||
| -$109.52M-75.0% | -$100.23M-95.3% | -$90.87M-119% | -$78.18M-112% | -$62.59M-84.9% | ||
| $106K+26.2% | $126K— | $97K— | $105K— | $84K— | ||
| -$183.15M— | -$241.24M— | -$267.68M— | -$287.98M— | —— | ||
| $314.92M+44.4% | $40.7M-88.6% | $40.13M-88.7% | $257.82M+86.2% | $218.14M+57.6% | ||
| —— | —— | -$319.44M— | -$109.37M— | —— | ||
| -$109.63M-74.9% | -$100.36M-95.9% | -$90.97M-120% | -$78.29M-112% | -$62.67M-84.6% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where does Dianthus Therapeutics's cash flow data come from?
- Every line is extracted from Dianthus Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.